Recursion Pharmaceuticals, Inc. (RXRX) Discusses Updated Safety and Efficacy Data from TUPELO Phase I/II Study of REC-4881 in FAP December 8, 2025 8:00 AM EST
Company Participants
Najat Khan - Chief R&D Officer, Chief Commercial Officer and Director Beth Bruckheimer David Mauro - Chief Medical Officer
Conference Call Participants
Jessica Stout Alfred Cohen
Presentation
Najat Khan Chief R&D Officer, Chief Commercial Officer and Director
Hi, everyone, and welcome. I’m Najat Khan, Recursion’s Chief R&D and Chief Commercial Officer and incoming CEO and President. Let’s jump right in. Today is an important mo…
Recursion Pharmaceuticals, Inc. (RXRX) Discusses Updated Safety and Efficacy Data from TUPELO Phase I/II Study of REC-4881 in FAP December 8, 2025 8:00 AM EST
Company Participants
Najat Khan - Chief R&D Officer, Chief Commercial Officer and Director Beth Bruckheimer David Mauro - Chief Medical Officer
Conference Call Participants
Jessica Stout Alfred Cohen
Presentation
Najat Khan Chief R&D Officer, Chief Commercial Officer and Director
Hi, everyone, and welcome. I’m Najat Khan, Recursion’s Chief R&D and Chief Commercial Officer and incoming CEO and President. Let’s jump right in. Today is an important moment for Recursion, for our teams and most importantly, for the FAP patient community. We are here to share updated safety and efficacy results from our ongoing Phase I/II TUPELO study evaluating REC-4881 in FAP.
Before we begin, please note that today’s presentation includes forward-looking statements about an investigational asset. Actual results may differ materially, and I encourage you to review our SEC filings for a full discussion of risks and uncertainties. What you will see today is proof points of the arc we’ve been building towards at Recursion from an unbiased platform insight to emerging clinical evidence, and we are very pleased to showcase that through the positive Phase Ib/II results from this ongoing study.
First, the unmet need in FAP is undeniable. FAP affects more than 50,000 patients across the U.S. and EU5. And as often is the case in rare diseases, the true prevalence may be higher once medical therapies become available and the diagnostic rate goes up. Most patients face a lifetime of escalating interventions from frequent surveillance, endoscopies and repeated excision of precancerous polyps and adenomas, which ultimately leads to a series of ever more debilitating life-altering surgeries such as the Whipple procedure. Today, there are no approved pharmacotherapies for FAP. And the natural history work our team completed with the University of Amsterdam Medical Center reinforces